Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial
Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Purpose:
To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the
H1-receptor antagonist ebastine.
Design:
Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment
with ebastine 20mg once daily or placebo (1:1 randomization).